Equities

INOVIQ Ltd

INOVIQ Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.495
  • Today's Change0.01 / 2.06%
  • Shares traded66.84k
  • 1 Year change-8.33%
  • Beta1.8392
Data delayed at least 20 minutes, as of May 09 2024 06:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.

  • Revenue in AUD (TTM)751.54k
  • Net income in AUD-6.51m
  • Incorporated1983
  • Employees85.00
  • Location
    INOVIQ Ltd23 Normanby Road, Notting HillNEDLANDS 3168AustraliaAUS
  • Phone+61 39548-7586
  • Fax+61 89388-7559
  • Websitehttps://www.inoviq.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lumos Diagnostics Holdings Ltd12.45m-13.37m24.55m----1.75--1.97-0.0359-0.03590.03540.02910.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
LBT Innovations Limited2.00m-21.38m26.79m17.00--9.87--13.37-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Cann Group Ltd16.45m-29.28m27.12m40.00--0.5339--1.65-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Alterity Therapeutics Ltd123.46k-12.28m31.47m11.00--0.9541--254.91-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Invion Ltd4.46m-1.50m32.12m8.00--1.80--7.20-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
IDT Australia Limited10.36m-6.55m34.44m156.00--1.49--3.33-0.022-0.0220.0350.06560.37412.393.51---23.64-9.87-26.41-11.5776.3884.42-63.19-24.942.81--0.0907---42.03-11.97-632.59---26.04--
Prescient Therapeutics Ltd697.94k-7.74m34.63m3.00--1.53--49.62-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Cynata Therapeutics Ltd436.25k-13.65m42.21m0.00--3.44--96.76-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Little Green Pharma Ltd23.24m-3.14m42.25m----0.520663.231.82-0.011-0.01260.08330.26890.2631.1312.06---3.55---4.01--51.02---13.51--2.03-21.270.0667--------------
Inoviq Ltd751.54k-6.51m44.63m85.00--2.67--59.38-0.0708-0.07080.00820.1820.03392.100.873---29.33-47.68-32.18-50.7695.07---866.27-2,527.824.93--0.0332--119.59153.3150.71------
Anteotech Ltd526.75k-11.46m50.58m40.00--9.71--96.02-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
Starpharma Holdings Ltd10.63m-8.40m51.51m50.00--1.49--4.85-0.0205-0.02050.02590.08370.20920.2822.10---16.53-28.47-20.70-33.6692.6771.62-79.00-391.825.22--0.0833---14.10-3.223.19--11.58--
Vitura Health Ltd119.67m9.40m52.98m121.005.591.3514.010.44270.01650.01650.20990.06811.9811.2210.51989,034.2015.2515.2922.3021.0631.23--7.706.921.185,598.190.2359--75.16--128.31146.9554.86--
Biotron Ltd1.65m-4.02m54.14m4.00--28.96--32.91-0.0045-0.00450.00180.00210.3587-------87.73-64.30-103.46-74.43-156.30-108.03-244.54-231.62----0.0148---8.16-2.48-25.59------
Biome Australia Ltd10.24m-2.86m61.72m30.00--28.63--6.03-0.0141-0.01410.05060.01011.371.936.04341,434.70-38.27---74.60--61.29---27.97--0.9514-15.920.4032--73.58--32.20------
Data as of May 09 2024. Currency figures normalised to INOVIQ Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

14.22%Per cent of shares held by top holders
HolderShares% Held
Merchant Funds Management Pty Ltd.as of 30 Nov 202213.08m14.22%
Data from 18 Mar 2024 - 18 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.